Last $0.91 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:30 PM 03/29/14 All times are local (Market data is delayed by at least 15 minutes).

artventive medical group inc (AVTD) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

artventive medical group inc (AVTD) Related Businessweek News

No Related Businessweek News Found

artventive medical group inc (AVTD) Details

ArtVentive Medical Group, Inc., a medical device corporation, focuses on developing, manufacturing, and marketing endoluminal occlusion devices (EOS). The company’s EOS devices are used in various clinical areas, including women's health, peripheral and neurological vascular disorders, interventional cardiology procedures, and pulmonary and interventional oncology. The company was formerly known as Uranium Plus Resources Inc. and changed its name to ArtVentive Medical Group, Inc. in January 2010. The company was founded in 2007 and is headquartered in Carlsbad, California.

artventive medical group inc (AVTD) Top Compensated Officers

Chairman, Chief Executive Officer and Chief F...
Total Annual Compensation: --
President, Chief Technology Officer and Direc...
Total Annual Compensation: --
Director of Sales for Europe
Total Annual Compensation: --
Regional Sales Director for Eastern Region - ...
Total Annual Compensation: --
Senior Vice President of Global Marketing and...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

artventive medical group inc (AVTD) Key Developments

Artventive Medical Group, Inc. Appoints Joe Harsa as Regional Sales Director for Eastern Region

Artventive Medical Group, Inc. announced the addition of Mr. Joe Harsa to its sales organization as Regional Sales Director for the Eastern Region of the U.S. Most recently Joe was with the Peripheral Vascular division of Boston Scientific, where he performed in key sales and sales management positions over a fourteen-year tenure.

ArtVentive Medical Group, Inc. Receives U.S. Food and Drug Administration Clearance for the Endoluminal Occlusion System

ArtVentive Medical Group, Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for the Endoluminal Occlusion System (EOSTM). Designed for use in the peripheral vasculature, the EOSTM offers immediate, complete and total occlusion in arterial and venous settings.

Artventive Medical Group, Inc., Annual General Meeting, Nov 26, 2014

Artventive Medical Group, Inc., Annual General Meeting, Nov 26, 2014., at 10:00 Pacific Standard Time. Location: at Eichenbaum, Comer & Ratynets, AAC, 20501 Ventura Blvd.. Agenda: To elect all members of the Board of Directors; to approve Anderson Bradshaw, PLLC as the company's independent auditors for the coming year; to approve a 2014 Stock Option Plan for Employees and Consultants approved by the Board of Directors; and to transact such other business as may properly come before the annual meeting and any adjournment or postponement thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVTD:US $0.91 USD 0.00

AVTD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVTD.
View Industry Companies

Industry Analysis


Industry Average

Valuation AVTD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 782.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 750.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARTVENTIVE MEDICAL GROUP INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at